RECORD // Company

Rani Therapeutics Holdings, Inc.

Built 2026-11-22T00:33:46Z from public sources · JSON · Open the company profile

ASK THE RECORDS

Ask

COMPANY

Records for this company (1 joined by official identifier)

Every record below is joined to this company by a hard identifier: its SEC registrant record or its GLEIF ownership tree. Each line says how. Built 2026-11-18 13:42:42. Beta: records that match only by name are held apart until name matching is verified.

SEC EDGAR (1)

5 VALUES · 10-Q · EACH LINKS TO ITS FILING

Latest quarter

Latest report: 10-Q for the period ended 2026-09-30, filed 2026-11-09 · accession 0001193125-26-453872

ItemValuePeriodFormFiledAccessionReport
Revenue$1,707,0003 months ended 2026-09-3010-Q2026-11-090001193125-26-4538722026-11-22 00:33 UTCReport an error
Net income (loss)$-7,729,0003 months ended 2026-09-3010-Q2026-11-090001193125-26-4538722026-11-22 00:33 UTCReport an error
Interest expense$43,0003 months ended 2026-09-3010-Q2026-11-090001193125-26-4538722026-11-22 00:33 UTCReport an error
Cash and cash equivalents$3,620,000at 2026-09-3010-Q2026-11-090001193125-26-4538722026-11-22 00:33 UTCReport an error
Debt due in the next 12 months (from an earlier report)$10,000,000at 2025-09-3010-Q2025-11-060001193125-25-2697742026-11-22 00:33 UTCReport an error

Negative as reported in the filing.

Values as filed in XBRL (SEC company facts); quarterly values are the filer's 3-month figures, never derived.

IDS

Identifiers

SEC CIK
0001856725
Ticker
RANI
EIN
863114789
CUSIP
753018100
Record ID
sx:sec:0001856725

OTHER SITES · YOUR CLICK · THEY SHOW THEIR OWN DATA

Open in

Open in…

Each link opens the other site in a new tab, with this company filled in. That site shows its own data under its own terms; Seraphix stores none of it. Seraphix counts clicks per link, nothing about who clicked.

33 FACTS · EACH LINKS TO ITS FILING

Facts

FactValueAs ofSourceRetrievedReport
SEC entity typeoperating2026-11-12SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
SIC industry2834 Pharmaceutical Preparations2026-11-12SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
Fiscal year end (MMDD)12312026-11-12SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
Business address47709 FREMONT BLVD, FREMONT, CA, 945382026-11-12SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
ExchangesNasdaq2026-11-12SEC EDGAR company profile2026-11-22 00:33 UTCReport an error
Revenue (fiscal year ended 2025-12-31)$1,633,0002025-12-3110-K, XBRL RevenueFromContractWithCustomerExcludingAssessedTax2026-11-22 00:33 UTCReport an error
Net income (loss) (fiscal year ended 2025-12-31)$-29,673,0002025-12-3110-K, XBRL NetIncomeLoss2026-11-22 00:33 UTCReport an error
Total assets (at 2025-12-31)$58,621,0002025-12-3110-K, XBRL Assets2026-11-22 00:33 UTCReport an error
Stockholders' equity (at 2025-12-31)$33,010,0002025-12-3110-K, XBRL StockholdersEquity2026-11-22 00:33 UTCReport an error
Cash and cash equivalents (at 2025-12-31)$18,618,0002025-12-3110-K, XBRL CashAndCashEquivalentsAtCarryingValue2026-11-22 00:33 UTCReport an error
Operating cash flow (fiscal year ended 2025-12-31)$-18,714,0002025-12-3110-K, XBRL NetCashProvidedByUsedInOperatingActivities2026-11-22 00:33 UTCReport an error
Capital expenditures (property, plant and equipment) (fiscal year ended 2025-12-31)$88,0002025-12-3110-K, XBRL PaymentsToAcquirePropertyPlantAndEquipment2026-11-22 00:33 UTCReport an error
Long-term debt (at 2025-12-31)$02025-12-3110-K, XBRL LongTermDebtNoncurrent2026-11-22 00:33 UTCReport an error
Remaining performance obligation (at 2025-12-31)$02025-12-3110-K, XBRL RevenueRemainingPerformanceObligation2026-11-22 00:33 UTCReport an error
Operating lease liabilities (at 2025-12-31)$4,318,0002025-12-3110-K, XBRL OperatingLeaseLiability2026-11-22 00:33 UTCReport an error
Form D total offering amount (D filed 2025-11-10)$60,255,0522025-11-10D2026-11-22 00:33 UTCReport an error
Form D total amount sold (D filed 2025-11-10)$60,255,0522025-11-10D2026-11-22 00:33 UTCReport an error
Form D industry groupBiotechnology2025-11-10D2026-11-22 00:33 UTCReport an error
Form D revenue rangeDecline to Disclose2025-11-10D2026-11-22 00:33 UTCReport an error
Form D date of first sale2025-10-232025-11-10D2026-11-22 00:33 UTCReport an error
8-K Item 3.01, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (filed 2026-11-12)As previously disclosed, on May 11, 2026, Rani Therapeutics Holdings, Inc. (the “Company”) received a letter from the Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, based upon the closing bid price of the Company’s Class A common stock for the preceding 30 consecutive business days, the Company was not in compliance with Nasdaq Listing Rule 5450(a)(1), which requires listed securities to maintain a minimum closing bid price of $1.00 per share (the “Minimum Bid Price Requirement”). The Company was initially provided 180 calendar days, or until November 9, 2026, to regain compliance with the Minimum Bid Price Requirement. On November 10, 2026, the Company received written…2026-11-12SEC EDGAR 8-K 0001193125-26-458489 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-11-09)On November 9, 2026, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the three and nine months ended September 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 2.02, including the press release attached as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any…2026-11-09SEC EDGAR 8-K 0001193125-26-453804 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
8-K Item 2.02, Results of Operations and Financial Condition (filed 2026-08-13)On August 13, 2026, Rani Therapeutics Holdings, Inc. (the “Company”) issued a press release providing a corporate update and announcing its financial results for the three and six months ended June 30, 2026. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in Item 2.02, including the press release attached as Exhibit 99.1 hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of…2026-08-13SEC EDGAR 8-K 0001193125-26-349197 (text as filed, excerpt)2026-11-22 00:33 UTCReport an error
Largest institutional holder #1 (13F as filed): SAMSARA BIOCAPITAL, LLC$7,884,7092026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #2 (13F as filed): RA CAPITAL MANAGEMENT, L.P.$6,463,4002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #3 (13F as filed): AWM Investment Company, Inc.$5,703,0002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #4 (13F as filed): VANGUARD CAPITAL MANAGEMENT LLC$3,467,8692026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #5 (13F as filed): Longaeva Partners L.P.$1,771,3212026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #6 (13F as filed): Polar Asset Management Partners Inc.$1,763,0192026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #7 (13F as filed): Siren, L.L.C.$1,520,8002026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #8 (13F as filed): HEIGHTS CAPITAL MANAGEMENT, INC$710,6552026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #9 (13F as filed): GEODE CAPITAL MANAGEMENT, LLC$677,5752026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error
Largest institutional holder #10 (13F as filed): CITADEL ADVISORS LLC$488,1732026-06-30SEC Form 13F data sets (quarterly; holdings as filed)2026-11-22 00:33 UTCReport an error

EVERY DATED RECORD, NEWEST FIRST

Timeline

WHAT IS NOT HERE

Gaps

SOURCES AND LICENSE

Sources

CC BY 4.0 -- credit Seraphix Systems.

API

Use this record

Records are free to read and reuse under CC BY 4.0 -- credit Seraphix Systems. The same records as JSON: GET /v1/search?q= and GET /v1/record/<id> (without a key, up to 50 record lookups a day per visitor). No key: single records, pages, feeds and bulk files are free; cross-company search and the live stream cost $0.002 a call via x402. Free key: 100 calls a month, no card. Get a free key or a paid key; send Authorization: Bearer <key>.